Arcus Biosciences RCUS Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions
Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions.
The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcus Biosciences's debt securities, available-for-sale, unrealized loss position, number of positions.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcus Biosciences's debt securities, available-for-sale, unrealized loss position, number of positions?
- Arcus Biosciences (RCUS) reported debt securities, available-for-sale, unrealized loss position, number of positions of $100 in Q1 2026.
- How has Arcus Biosciences's debt securities, available-for-sale, unrealized loss position, number of positions changed year-over-year?
- Arcus Biosciences's debt securities, available-for-sale, unrealized loss position, number of positions increased by 40.8% year-over-year, from $71 to $100.
- What is the long-term trend for Arcus Biosciences's debt securities, available-for-sale, unrealized loss position, number of positions?
- Over 3 years (2022 to 2025), Arcus Biosciences's debt securities, available-for-sale, unrealized loss position, number of positions has grown at a -47.9% compound annual growth rate (CAGR), from $219 to $31.